Journal Article
. 2019 Feb;20(3).
doi: 10.1016/S1470-2045(18)30812-X.

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial

Sherene Loi 1 Anita Giobbie-Hurder 2 Andrea Gombos 3 Thomas Bachelot 4 Rina Hui 5 Giuseppe Curigliano 6 Mario Campone 7 Laura Biganzoli 8 Hervé Bonnefoi 9 Guy Jerusalem 10 Rupert Bartsch 11 Manuela Rabaglio-Poretti 12 Roswitha Kammler 13 Rudolf Maibach 14 Mark J Smyth 15 Angelo Di Leo 16 Marco Colleoni 17 Giuseppe Viale 18 Meredith M Regan 19 Fabrice André 20 International Breast Cancer Study Group and the Breast International Group  
  • PMID: 30765258
  •     46 citations


Background: HER2-positive breast cancers usually contain large amounts of T-cell infiltrate. We hypothesised that trastuzumab resistance in HER2-positive breast cancer could be mediated by immune mechanisms. We assessed the safety and anti-tumour activity of pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, added to trastuzumab in trastuzumab-resistant, advanced HER2-positive breast cancer.

Methods: We did this single-arm, multicentre, phase 1b-2 trial in 11 centres based in five countries. Eligible participants were women aged 18 years or older, who had advanced, histologically confirmed, HER2-positive breast cancer; documented progression during previous trastuzumab-based therapy; an Eastern Cooperative Oncology Group performance status of 0 or 1; and a formalin-fixed, paraffin-embedded metastatic tumour biopsy for central assessment of programmed cell death 1 ligand 1 (PD-L1) status. In phase 1b, we enrolled patients with PD-L1-positive tumours in a 3 + 3 dose-escalation of intravenous pembrolizumab (2 mg/kg and 10 mg/kg, every 3 weeks) plus 6 mg/kg of intravenous trastuzumab. The primary endpoint of the phase 1b study was the incidence of dose-limiting toxicity and recommended phase 2 dose; however, a protocol amendment on Aug 28, 2015, stipulated a flat dose of pembrolizumab of 200 mg every 3 weeks in all Merck-sponsored trials. In phase 2, patients with PD-L1-positive and PD-L1-negative tumours were enrolled in parallel cohorts and received the flat dose of pembrolizumab plus standard trastuzumab. The primary endpoint of the phase 2 study was the proportion of PD-L1-positive patients achieving an objective response. This trial is registered in, number NCT02129556, and with EudraCT, number 2013-004770-10, and is closed.

Findings: Between Feb 2, 2015, and April 5, 2017, six patients were enrolled in phase 1b (n=3 received 2 mg/kg pembrolizumab, n=3 received 10 mg/kg pembrolizumab) and 52 patients in phase 2 (n=40 had PD-L1-positive tumours, n=12 had PD-L1-negative tumours). The data cutoff for this analysis was Aug 7, 2017. During phase 1b, there were no dose-limiting toxicities in the dose cohorts tested. Median follow-up for the phase 2 cohort was 13·6 months (IQR 11·6-18·4) for patients with PD-L1-positive tumours, and 12·2 months (7·9-12·2) for patients with PD-L1-negative tumours. Six (15%, 90% CI 7-29) of 40 PD-L1-positive patients achieved an objective response. There were no objective responders among the PD-L1-negative patients. The most common treatment-related adverse event of any grade was fatigue (12 [21%] of 58 patients). Grade 3-5 adverse events occurred in 29 (50%) of patients, treatment-related grade 3-5 adverse events occurred in 17 (29%), and serious adverse events occurred in 29 (50%) patients. The most commonly occurring serious adverse events were dyspnoea (n=3 [5%]), pneumonitis (n=3 [5%]), pericardial effusion (n=2 [3%]), and upper respiratory infection (n=2 [3%]). There was one treatment-related death due to Lambert-Eaton syndrome in a PD-L1-negative patient during phase 2.

Interpretation: Pembrolizumab plus trastuzumab was safe and showed activity and durable clinical benefit in patients with PD-L1-positive, trastuzumab-resistant, advanced, HER2-positive breast cancer. Further studies in this breast cancer subtype should focus on a PD-L1-positive population and be done in less heavily pretreated patients.

Funding: Merck, International Breast Cancer Study Group.

A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
Stephen Chia, Phillipe L Bedard, +8 authors, Lesley Seymour.
Oncologist, 2019 Aug 20; 24(11). PMID: 31420468    Free PMC article.
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer.
David B Page, Harry Bear, +19 authors, Sylvia Adams.
NPJ Breast Cancer, 2019 Oct 12; 5. PMID: 31602395    Free PMC article.
PD-1-Associated Gene Expression Signature of Neoadjuvant Trastuzumab-Treated Tumors Correlates with Patient Survival in HER2-Positive Breast Cancer.
William P D Hendricks, Natalia Briones, +4 authors, Suwon Kim.
Cancers (Basel), 2019 Oct 18; 11(10). PMID: 31618954    Free PMC article.
Targeted and novel therapy in advanced gastric cancer.
Julie H Selim, Shagufta Shaheen, Wei-Chun Sheu, Chung-Tsen Hsueh.
Exp Hematol Oncol, 2019 Oct 22; 8. PMID: 31632839    Free PMC article.
Targeted therapeutic options and future perspectives for HER2-positive breast cancer.
Jiani Wang, Binghe Xu.
Signal Transduct Target Ther, 2019 Oct 23; 4. PMID: 31637013    Free PMC article.
Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy.
Deepak Mittal, Dipti Vijayan, +5 authors, Mark J Smyth.
Oncoimmunology, 2019 Oct 28; 8(11). PMID: 31646095    Free PMC article.
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives.
E Krasniqi, G Barchiesi, +17 authors, P Vici.
J Hematol Oncol, 2019 Oct 31; 12(1). PMID: 31665051    Free PMC article.
Immune checkpoint inhibitors in gastrointestinal malignancies: what can we learn from experience with other tumors?
Anand B Shah, Katelyn R Sommerer, Khaldoun Almhanna.
Transl Gastroenterol Hepatol, 2019 Nov 16; 4. PMID: 31728430    Free PMC article.
Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.
Ana Godoy-Ortiz, Alfonso Sanchez-Muñoz, +4 authors, Emilio Alba.
Front Oncol, 2019 Nov 19; 9. PMID: 31737566    Free PMC article.
Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study.
Takayuki Ueno, Norikazu Masuda, +10 authors, Masakazu Toi.
Jpn J Clin Oncol, 2019 Dec 11; 50(1). PMID: 31821506    Free PMC article.
Biologically Aggressive Phenotype and Anti-cancer Immunity Counterbalance in Breast Cancer with High Mutation Rate.
Hideo Takahashi, Mariko Asaoka, +5 authors, Kazuaki Takabe.
Sci Rep, 2020 Feb 07; 10(1). PMID: 32024876    Free PMC article.
Current status and limitations of immunotherapy for breast cancer.
Yoshihisa Tokumaru, Daniel Joyce, Kazuaki Takabe.
Surgery, 2019 Oct 19; 167(3). PMID: 31623855    Free PMC article.
High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities.
Ioannis A Voutsadakis.
Target Oncol, 2019 Nov 20; 15(1). PMID: 31741177
Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond.
Ricardo L B Costa, Brian J Czerniecki.
NPJ Breast Cancer, 2020 Mar 21; 6. PMID: 32195333    Free PMC article.
Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.
Noam Pondé, Philippe Aftimos, Martine Piccart.
Curr Treat Options Oncol, 2019 Apr 02; 20(5). PMID: 30931493
PD-1/PD-L1 pathway: current researches in cancer.
Yanyan Han, Dandan Liu, Lianhong Li.
Am J Cancer Res, 2020 Apr 09; 10(3). PMID: 32266087    Free PMC article.
Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models.
Regina Padmanabhan, Hadeel Shafeeq Kheraldine, +2 authors, Ala-Eddin Al Moustafa.
Cancers (Basel), 2020 Mar 14; 12(3). PMID: 32164163    Free PMC article.
Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
Krithika N Kodumudi, Ganesan Ramamoorthi, +10 authors, Brian J Czerniecki.
Front Immunol, 2019 Sep 03; 10. PMID: 31475002    Free PMC article.
Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1.
Jing Zhao, Jian Huang.
Chin Med J (Engl), 2020 Feb 28; 133(7). PMID: 32106121    Free PMC article.
Combination Strategies of Checkpoint Immunotherapy in Metastatic Breast Cancer.
Zhi Bing Liu, Luyan Zhang, Jia Bian, Jinbo Jian.
Onco Targets Ther, 2020 Apr 21; 13. PMID: 32308409    Free PMC article.
Biomarkers of immune checkpoint inhibitor efficacy in cancer.
D E Meyers, S Banerji.
Curr Oncol, 2020 May 06; 27(Suppl 2). PMID: 32368180    Free PMC article.
The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies.
Jordyn Kreutzfeldt, Brett Rozeboom, Nandini Dey, Pradip De.
Am J Cancer Res, 2020 May 06; 10(4). PMID: 32368385    Free PMC article.
HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development.
Atefeh Arab, Rezvan Yazdian-Robati, Javad Behravan.
Arch Immunol Ther Exp (Warsz), 2020 Jan 10; 68(1). PMID: 31915932    Free PMC article.
The premise of personalized immunotherapy for cancer dormancy.
Masoud H Manjili.
Oncogene, 2020 Apr 24; 39(22). PMID: 32322001    Free PMC article.
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Jieqiong Liu, Qiang Liu, +10 authors, Erwei Song.
J Immunother Cancer, 2020 May 26; 8(1). PMID: 32448804    Free PMC article.
The future of cancer immunotherapy: microenvironment-targeting combinations.
Yonina R Murciano-Goroff, Allison Betof Warner, Jedd D Wolchok.
Cell Res, 2020 May 30; 30(6). PMID: 32467593    Free PMC article.
DGM-CM6: A New Model to Predict Distant Recurrence Risk in Operable Endocrine-Responsive Breast Cancer.
Lei Lei, Xiao-Jia Wang, +2 authors, Yunyun Zhou.
Front Oncol, 2020 Jun 13; 10. PMID: 32528885    Free PMC article.
A Novel 4-Gene Score to Predict Survival, Distant Metastasis and Response to Neoadjuvant Therapy in Breast Cancer.
Masanori Oshi, Eriko Katsuta, +5 authors, Kazuaki Takabe.
Cancers (Basel), 2020 May 07; 12(5). PMID: 32370309    Free PMC article.
Triple negative breast cancer: special histological types and emerging therapeutic methods.
Lu Cao, Yun Niu.
Cancer Biol Med, 2020 Jun 27; 17(2). PMID: 32587770    Free PMC article.
Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?
Cinzia Solinas, Marco Aiello, +3 authors, Edoardo Migliori.
Transl Oncol, 2020 Jul 06; 13(10). PMID: 32622310    Free PMC article.
Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies.
Josée Golay, Alain E Andrea.
Antibodies (Basel), 2020 May 24; 9(2). PMID: 32443877    Free PMC article.
Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach.
Yacine Bareche, Laurence Buisseret, +9 authors, Christos Sotiriou.
J Natl Cancer Inst, 2019 Oct 31; 112(7). PMID: 31665482    Free PMC article.
New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?pi.
Essia Mezni, Cécile Vicier, +3 authors, Anthony Gonçalves.
Cancers (Basel), 2020 Jun 18; 12(6). PMID: 32545895    Free PMC article.
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.
Andrea Botticelli, Alessio Cirillo, +18 authors, Paolo Marchetti.
Vaccines (Basel), 2020 May 02; 8(2). PMID: 32353934    Free PMC article.
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
Michelle D Hackshaw, Heather E Danysh, +6 authors, Charles A Powell.
Breast Cancer Res Treat, 2020 Jun 28; 183(1). PMID: 32591987    Free PMC article.
The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2- Breast Cancer.
Masanori Oshi, Hideo Takahashi, +6 authors, Kazuaki Takabe.
Cells, 2020 Jul 12; 9(7). PMID: 32650578    Free PMC article.
Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis.
Yutian Zou, Xuxiazi Zou, +4 authors, Xiaoming Xie.
Ther Adv Med Oncol, 2020 Sep 03; 12. PMID: 32874208    Free PMC article.
The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer.
Aena Patel, Nisha Unni, Yan Peng.
Cancers (Basel), 2020 Aug 01; 12(8). PMID: 32731409    Free PMC article.
Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer.
Junnan Xu, Hua Bao, +3 authors, Tao Sun.
Oncol Lett, 2019 Jul 11; 18(1). PMID: 31289516    Free PMC article.
DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy.
Elaine Gilmore, Nuala McCabe, Richard D Kennedy, Eileen E Parkes.
J Oncol, 2019 Jul 20; 2019. PMID: 31320901    Free PMC article.
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review.
Gabrielle Planes-Laine, Philippe Rochigneux, +4 authors, Anthony Gonçalves.
Cancers (Basel), 2019 Jul 25; 11(7). PMID: 31336685    Free PMC article.
Highly Cited. Review.
Monoclonal Antibodies in Cancer Therapy.
David Zahavi, Louis Weiner.
Antibodies (Basel), 2020 Jul 24; 9(3). PMID: 32698317    Free PMC article.
Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress.
Valentina Gambardella, Tania Fleitas, +6 authors, Andrés Cervantes.
J Clin Med, 2020 Sep 26; 9(9). PMID: 32971757    Free PMC article.
Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets.
Hussein F Aqbi, Cara Coleman, +11 authors, Masoud H Manjili.
Breast Cancer Res, 2020 Oct 30; 22(1). PMID: 33115528    Free PMC article.
Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options.
Simon Peter Gampenrieder, Vanessa Castagnaviz, Gabriel Rinnerthaler, Richard Greil.
Cancer Manag Res, 2020 Nov 06; 12. PMID: 33149670    Free PMC article.
Clinical Data on Immunotherapy in Breast Cancer.
Julia Caroline Radosa, Lisa Stotz, +3 authors, Marc Philipp Radosa.
Breast Care (Basel), 2020 Nov 24; 15(5). PMID: 33223989    Free PMC article.